Wound dressing components degrade proteins detrimental to wound healing

International Wound Journal

Volumn 5, Issue 4, 2008, Pages 543-551

  Baskovich, Brett ^a   Sampson, Edith M ^a   Schultz, Gregory S ^a   Parnell, Laura K S ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b Precision Consulting   (United States)

Author keywords

Inflammation; MMP; Protease; TNF ; Wound

Indexed keywords

COLLAGENASE; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; PLATELET DERIVED GROWTH FACTOR; PROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; INCUBATION TIME; PRIORITY JOURNAL; PROTEIN DEGRADATION; TEMPERATURE SENSITIVITY; WOUND CLOSURE; WOUND DRESSING; WOUND FLUID; WOUND HEALING; ZYMOGRAPHY;

ANALYSIS OF VARIANCE; BANDAGES; CHEMISTRY, PHARMACEUTICAL; CHRONIC DISEASE; CYTOKINES; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXUDATES AND TRANSUDATES; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; MATRIX METALLOPROTEINASES; PEPTIDE HYDROLASES; PLATELET-DERIVED GROWTH FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR NECROSIS FACTOR-ALPHA; WOUND HEALING;

EID: 54249109512     PISSN: 17424801     EISSN: 1742481X     Source Type: Journal    
DOI: 10.1111/j.1742-481X.2007.00422.x     Document Type: Article

References (21)

1. Mast BA, Schultz GS. Interactions of cytokines, growth factors, and proteases in acute and chronic wound fluid. Wound Repair Regen 1996 4 : 411 20.
2. Falanga V. The chronic wound: failure to heal. In : Falanga V, editor. Cutaneous wound healing. Florence : Martin Dunitz Ltd, 2001 : 155 64.
3. Falanga V, Brem H. Wound bed preparation for optimal use of advanced therapeutic products. In : Falanga V, editor. Cutaneous wound healing. Florence : Martin Dunitz Ltd, 2001 : 457 68.
4. Mahendale F, Martin P. The cellular and molecular events of wound healing. In : Falanga V, editor. Cutaneous wound healing. Florence : Martin Dunitz Ltd, 2001 : 15 37.
5. Efron PA, Moldawer LL. Cytokines and wound healing: the role of cytokines and anticytokine therapy in the repair response. J Burn Care Rehab 2004 25 : 149 60.
6. Mast BA. The skin. In : Cohen IK, Diegelmann RF, Lindblad WJ, editors. Wound healing: biochemical and clinical perspective. Philadelphia : WB Saunders Company, Harcourt Brace Jovanovich Inc., 1992 : 344 55.
7. Tarnuzzer RW, Schultz GS. Biochemical analysis of acute and chronic wound environments. Wound Repair Regen 1996 4 : 321 25.
8. Danon D, Kowatch MA, Roth GS. Promotion of repair in old mice by local injection of macrophages. Proc Natl Acad Sci U S A 1989 86 : 2018 20.
9. Leibovich SJ, Ross R. The role of the macrophage in wound repair; a study with hydrocortisone and antimacrophage serum. Am J Pathol 1975 78 : 71 91.
10. Cullen B, Smith R, McCulloch E, Silcock D, Morrison L. Mechanism of action of Promogran, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair Regen 2002 10 : 16 25.
11. Trengove NJ, Langton SR, Stacey MC. Biochemical analysis of wound fluid from nonhealing and healing chronic leg ulcers. Wound Repair Regen 1996 4 : 234 9.
12. Fu X, Li X, Cheng B, Chen W, Sheng Z. Engineered growth factors and cutaneous wound healing: success and possible questions in the past 10 years. Wound Repair Regen 2005 13 : 122 30.
13. Mustoe TA, Cutler NR, Allman RM. Phase II study to evaluate recombinant PDGF-BB in the treatment of pressure sores. Arch Surg 1994 129 : 213 9.
14. Steed DL, The Diabetic Ulcer Study Group. Clinical evaluation of recombinant human platelet derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg 1995 21 : 71 81.
15. Pierce GF, Tarpley JE, Tseng J. Detection of increased levels of PDGF-AA rh activity healing human wounds treated with recombinant PDGF-BB, and absence of PDGF in chronic nonhealing wounds. J Clin Invest 1995 96 : 1336 50.
16. Yager DR, Chen SM, Ward SI, Olutoye OO, Diegelmann RF, Cohen IK. Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors. Wound Repair Regen 1997 5 : 23 32.
17. Falanga V. Growth factors and chronic wounds: the need to understand the microenvironment. J Dermatol 1992 19 : 667 72.
18. U.S. Food and Drug Administration. Summary of All GRAS Notifications WWW document URL http://www.cfsan.fda.gov/∼rdb/opa-gras.html (Accessed 3 January 2008).
19. Phillips L. Therapeutic options in management of pressure ulcers. In : Falanga V, editor. Cutaneous wound healing. Florence : Martin Dunitz Ltd, 2001 : 343 56.
20. Barnett L, Parnell LKS. Contact dermatitis treated with new topical products: a case study. Ostomy Wound Manage 2001 47 : 47 53.
21. Parnell LKS, Ciufi B, Gokoo CF. Preliminary use of a hydrogel containing enzymes in the treatment of stage II and stage III pressure ulcers. Ostomy Wound Manage 2005 51 : 50 60.